RBC Capital analyst Brian Abrahams lowered the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $96.00 (from $100.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

JPMorgan on Intra-Cellular Therapies (ITCI): 'We continue to like ITCI stock'May 7, 2024 12:32 PM Jefferies Positive on Intra-Cellular Therapies (ITCI): 'We like the setup ahead of the second MDD readout in late-Q2'May 7, 2024 8:00 AM Form 10-Q Intra-Cellular Therapies For: Mar 31May 7, 2024 7:44 AM Form 8-K Intra-Cellular Therapies For: May 07May 7, 2024 7:41 AM Intra-Cellular Therapies (ITCI) Tops Q1 EPS by 16c ; Offers GuidanceMay 7, 2024 7:33 AM Intra-Cellular Therapies Reports First Quarter 2024 Financial ResultsMay 7, 2024 7:30 AM